Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

British journal of cancer - 1 Sept 2018

Bellmunt Joaquim, Lalani Aly-Khan A, Jacobus Sussana, Wankowicz Stephanie A, Polacek Laura, Takeda David Y, Harshman Lauren C, Wagle Nikhil, Moreno Irene, Lundgren Kevin, Bossé Dominick, Van Allen Eliezer M, Choueiri Toni K, Rosenberg Jonathan E

Abstract excerpt

BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients with mUC. METHODS: mUC patients enrolled on a Phase I dose escalation study and an expansion cohort treated with E/P...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Kidney Neoplasms

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Sulfonamides

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 30220708
DOI: 10.1038/s41416-018-0261-0
PMCID: PMC6173710

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.PMID 30220708Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CASemantic proximity Read ↗

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.Semantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.Semantic proximity Read ↗

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.Semantic proximity Read ↗

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Semantic proximity Read ↗

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy optionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.